![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Pelosi’s Drug Pricing Plan Would Give HHS Negotiation Muscle
Pelosi’s Drug Pricing Plan Would Give HHS Negotiation Muscle
![HHS logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/HHS_Logo2019.png?t=1617054201&width=430)
September 18, 2019
House Speaker Nancy Pelosi (D-Calif.) is expected to release a drug pricing bill that would give the government the power to directly negotiate the prices of the nation’s most costly prescription drugs.
HHS would get the authority to directly negotiate prices for the top 250 drugs most costly to Medicare and to “the entire U.S. health system” that lack at least two marketed copycat versions, according to a draft version of the Drug Price Negotiation Bill.
The draft claims that in just the first year, drugs accounting for nearly half of all Medicare Part D spending would be subject to negotiation, including insulins, whose high prices have been in the crosshairs of lawmakers. It would also cap negotiated drugs with an international price index at a maximum price “to ensure negotiations produce real price reductions.”
Upcoming Events
-
21Oct